75.14
0.03 (0.04%)
| Previous Close | 75.11 |
| Open | 74.98 |
| Volume | 1,004,190 |
| Avg. Volume (3M) | 3,239,531 |
| Market Cap | 16,761,146,368 |
| Price / Earnings (TTM) | 30.18 |
| Price / Earnings (Forward) | 16.42 |
| Price / Sales | 4.11 |
| Price / Book | 3.19 |
| 52 Weeks Range | |
| Earnings Date | 29 Jan 2026 |
| Profit Margin | 13.83% |
| Operating Margin (TTM) | 22.17% |
| Diluted EPS (TTM) | 2.38 |
| Quarterly Revenue Growth (YOY) | -1.20% |
| Quarterly Earnings Growth (YOY) | -18.50% |
| Total Debt/Equity (MRQ) | 54.80% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 1.13 B |
| Levered Free Cash Flow (TTM) | 775.88 M |
| Return on Assets (TTM) | 6.92% |
| Return on Equity (TTM) | 11.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Hologic, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.5 |
| Insider Activity | -1.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 102.61% |
| 52 Weeks Range | ||
| Median | 78.00 (3.81%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 05 Jan 2026 | 78.00 (3.81%) | Hold | 74.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HORVATH MARK W. | - | 75.15 | -113 | -8,492 |
| Aggregate Net Quantity | -113 | |||
| Aggregate Net Value ($) | -8,492 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 75.15 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HORVATH MARK W. | Officer | 10 Feb 2026 | Disposed (-) | 113 | 75.15 | 8,492 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |